Immuneering Corp (NASDAQ: IMRX) on Friday, soared 2.68% from the previous trading day, before settling in for the closing price of $5.6. Within the past 52 weeks, IMRX’s price has moved between $1.10 and $6.18.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -46.45% annually for the last half of the decade. The company achieved an average annual earnings per share of 19.12%. With a float of $26.05 million, this company’s outstanding shares have now reached $35.99 million.
Immuneering Corp (IMRX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Immuneering Corp is 28.28%, while institutional ownership is 10.54%. The most recent insider transaction that took place on Jul 02 ’25, was worth 10,874. In this transaction Director of this company bought 3,000 shares at a rate of $3.62, taking the stock ownership to the 3,000 shares. Before that another transaction happened on Jul 02 ’25, when Company’s Director bought 2,500 for $3.60, making the entire transaction worth $8,989. This insider now owns 2,500 shares in total.
Immuneering Corp (IMRX) Latest Financial update
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.49 earnings per share (EPS) for the period topping the consensus outlook (set at -0.55) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 19.12% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.59% during the next five years compared to -46.45% drop over the previous five years of trading.
Immuneering Corp (NASDAQ: IMRX) Trading Performance Indicators
Immuneering Corp (IMRX) is currently performing well based on its current performance indicators. A quick ratio of 3.70 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.90, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.63 in one year’s time.
Technical Analysis of Immuneering Corp (IMRX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.02 million. That was inferior than the volume of 1.25 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 78.13%.
During the past 100 days, Immuneering Corp’s (IMRX) raw stochastic average was set at 91.54%, which indicates a significant increase from 86.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.55 in the past 14 days, which was higher than the 0.29 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.88, while its 200-day Moving Average is $2.30. However, in the short run, Immuneering Corp’s stock first resistance to watch stands at $5.85. Second resistance stands at $5.95. The third major resistance level sits at $6.14. If the price goes on to break the first support level at $5.56, it is likely to go to the next support level at $5.37. The third support level lies at $5.27 if the price breaches the second support level.
Immuneering Corp (NASDAQ: IMRX) Key Stats
Market capitalization of the company is 208.83 million based on 36,319K outstanding shares. Right now, sales total 0 K and income totals -61,040 K. The company made 0 K in profit during its latest quarter, and -14,430 K in sales during its previous quarter.
